Galaxy completes enrolment in SEAL IT pivotal trial

Written by

admin

in


Galaxy Therapeutics has announced it has successfully completed enrolment in SEAL IT, the company’s US investigational device exemption (IDE) pivotal trial evaluating the Seal device for brain aneurysms. The multicentre,…

Continue Reading

More posts